Hence, whether targeting IL-6, downstream of IL-1 and IL-18, might quell inflammation with less impairment of host defenses, especially since IL-6 is causally involved in atherosclerosis, as shown by Mendelian randomization analysis (89), is an ongoing issue that warrants further investigation. This evidence concerns the gene IL1B and atherosclerosis.